(19) TZZ____T (11) EP 1 776 161 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61Q 5/02 (2006.01) A61Q 7/00 (2006.01) 26.10.2016 Bulletin 2016/43 A61Q 19/00 (2006.01) A61K 8/36 (2006.01) A61K 8/362 (2006.01) A61K 8/37 (2006.01) (2006.01) (2006.01) (21) Application number: 05718804.7 A61K 8/39 A61Q 1/02 A61Q 5/06 (2006.01) A61K 8/64 (2006.01) A61Q 5/12 (2006.01) A61Q 11/00 (2006.01) (22) Date of filing: 25.04.2005 A61K 8/81 (2006.01) A61Q 19/06 (2006.01) A61Q 19/08 (2006.01) A61K 8/97 (2006.01) A61K 8/42 (2006.01) A61K 8/49 (2006.01) A61Q 5/00 (2006.01) A61K 8/73 (2006.01) (86) International application number: PCT/IB2005/051344 (87) International publication number: WO 2005/102266 (03.11.2005 Gazette 2005/44) (54) COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE UDP GLUCURONOSYL TRANSFERASE (UGT) ENZYMES INDUCER KOSMETISCHE ODER DERMOPHARMAZEUTISCHE ZUSAMMENSETZUNG MIT MINDESTENS EINEM UDP-GLUCURONOSYL-TRANSFERASE (UGT) ENZYM-INDUKTOR COMPOSITION COSMETIQUE OU DERMOPHARMACEUTIQUE COMPRENANT AU MOINS UN INDUCTEUR D’ENZYMES UDP-GLUCURONOSYLTRANSFERASES (UGT) (84) Designated Contracting States: • PATENT ABSTRACTS OF JAPAN vol. 2000, no. DE ES FR GB IT 14, 5 March 2001 (2001-03-05) & JP 2000 319154 A(NIPPON MENAADEKESHOHIN KK; ICHIMARU (30) Priority: 26.04.2004 FR 0404408 PHARCOS CO LTD), 21 November 2000 (2000-11-21) (43) Date of publication of application: • DATABASE WPI Derwent Publications Ltd., 25.04.2007 Bulletin 2007/17 London, GB; AN 2001-481491 XP002309671 CHEOUNG J H ET AL.: "Chrysin 7-o-crotonate, its (73) Proprietor: Sederma S.A.S. producing method and composition useful for 78612 Le Perray-en-Yvelines Cedex (FR) hair growth tonic" & KR 2001 009 474 A (CHEOUNG J H, KIM P K) 5 February 2001 (72) Inventors: (2001-02-05) •LINTNER,Karl • ANONYMOUS: "Nutrasport Testroxin Gel" F-06500 Menton (FR) INTERNET ARTICLE, [Online] pages 1-2, • MAS, CHAMBERLIN, Claire XP002309667 Global-Nutrition-Inc. Retrieved F-78460 Chevreuse (FR) from the Internet: URL:http://www.bodybuilding-supplements-fo (56) References cited: r-you.com/nutrasport/testroxin-gel.htm> -& EP-A- 1 300 138 WO-A-00/67767 INTERNET ARTICLE, [Online] XP002312910 WO-A-2004/089392 DE-A- 10 009 424 Retrieved from the Internet: FR-A- 2 594 336 FR-A- 2 778 663 URL:http://web.archive.org/web/*/http://ww FR-A- 2 802 413 FR-A- 2 836 042 w.bodybuilding-supplements-for-you.com/nut rasport/testroxin-gel.htm> Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 1 776 161 B1 Printed by Jouve, 75001 PARIS (FR) (Cont. next page) EP 1 776 161 B1 • INTERNATIONAL ANTIAGING SYSTEMS: • DATABASE EMBASE [Online] ELSEVIER "ESTROGEN BLOCKERS" INTERNET ARTICLE, SCIENCE PUBLISHERS, AMSTERDAM, NL; 2002, [Online] pages 1-2, XP002309668 Retrieved from WALLE U K ET AL: "Induction of human the Internet: UDP-glucuronosyltransferase UGT1A1 by URL:http://www.antiaging-systems.com/a2z/e flavonoids - Structural requirements" strogenblock.htm> XP002309670 Database accession no. • AHN M-R, ET AL.: "Antioxidant activity and EMB-2002159263 & DRUG METABOLISM AND constituents of propolis collected in various DISPOSITION 2002 UNITED STATES, vol. 30, no. areas of Korea" JOURNAL OF AGRICULTURAL 5, 2002, pages 564-569, ISSN: 0090-9556 AND FOOD CHEMISTRY, vol. 52, 11 February 2004 (2004-02-11), pages 7286-7292, XP002309669 AMERICAN CHEMICAL SOCIETY 2 EP 1 776 161 B1 Description SUMMARY OF THE INVENTION 5 [0001] The invention concerns a new cosmetic or dermopharmaceutical composition to protect and/or enhance the state of the skin and prevent and/or treat imperfections of the skin. BACKGROUND OF THE INVENTION 10 [0002] Cosmetic products that temporarily improve the appearance of the skin by masking the irregularities with an opaque cosmetic film are available. This invention proposes an effective alternative to the use of those masking cosmetic products to prevent and/or treat skin that has aged and/or is subject to environmental aggression. [0003] Throughout life, each individual is subject to exposure to sunlight and air pollution either occasionally or to multiple and/or extreme exposures. The skin continuously suffers aggression from numerous extrinsic but also intrinsic 15 factors. The extrinsic factors include ultraviolet radiation (mainly linked to exposure to the sun: sunlight-induced aging), environmental pollution and atmospheric pollution, but also wind, heat, low relative humidity levels, contact with household surfactants and other chemicals, abrasives, smoking, alcohol, drugs, diet, stress, mechanical stress, severe atmospheric conditions and so on. The intrinsic factors include chronological aging and the other biochemical changes in the skin. The following may also be cited: hormonal upheavals, fatigue, acne, obesity, tanning, diets, disease, for example, 20 hyperbilirubinemia (jaundice), hematomas and disorders of the blood microcirculation. [0004] Whether extrinsic or intrinsic, those factors induce cosmetically undesirable impairment of the visible appear- ance, clinical and physical properties and physiological and histological functions of the skin and even give rise to visible signs of (premature or non-premature) aging of the skin. [0005] The most noteworthy and patent changes include dryness and the development of fine lines and wrinkles, loss 25 of elasticity, wasting and sagging of the skin, loss of firmness, thinning of the skin, loss of uniformity of the complexion, a dull complexion, hyperpigmentation, senile lentigines, red spots, a rough, coarse surface texture and a marbled pig- mentation. Dull and impaired hair, hair loss and an unbalanced scalp are also frequent symptoms. [0006] Other less obvious but nonetheless measurable changes occur when the skin ages or is subject to chronic environmental aggression and include a general reduction in the vitality of the tissues and cells, slowed cell replication, 30 a decrease in protein synthesis, an increase in proteolysis, a decrease in cutaneous blood circulation or vasodilatation with blood stasis, seepage from the blood compartment, reduced water content, an accumulation of errors in the structure and function of proteins, a deleterious change in the skin’s barrier properties, connective tissues and cohesion, and a reduced ability of the skin to remodel and repair itself. [0007] In particular, in the case of secondary effects related to accumulation of iron in the peripheral cutaneous tissues, 35 such as hyperbilirubinemia (jaundice, neonatal icterus), hematoma, and rings (or circles) under the eyes, pigmentation is promoted by the inadequate elimination of hemolysis products: violet-green appearance of biliverdin, brown-red- orange with bilirubin and mineral iron, violet with hemosiderin. [0008] For many people, an impaired or aged skin reminds them of the disappearance of youth. For that reason, our societies attribute great importance to apparent youth and fighting against deteriorated/damaged/imperfect skin has 40 become an economic issue. The treatments proposed range from functional cosmetic creams to cosmetic surgery. [0009] External factors, like internal factors, supply the body with a great variety of substances that are both exogenous (xenobiotics) and endogenous. Those substances, frequently lipophilic, have a high affinity for the skin that is itself lipid- based. The skin surface concentrates all the substances that impair the skin and contribute to its imperfection. [0010] WO2004/089392 discloses a composition comprising a mixture of two specific classes of compounds, Free- 45 B-Ring flavonoids and flavans, for use in the prevention and treatment of diseases and conditions associated with the skin. This composition simultaneously inhibits cyclooxygenase (COX) and lipoxygenase (LOX) enzymatic activity in normal, aged and damaged dermal cells and tissues. A formulation called Soliprin™ is disclosed comprising chrysin and chrysin-7-glucuronide among a mixture of Free-B-Ring flavonoids. In one proposed embodiment, the Free-B-Ring flavonoids are combined with a chelating agent (for example ETDA). 50 [0011] WO2004/030605 discloses a cosmetic cream comprising an extract of Prunus domestica containing chrysin and EDTA-4Na as chelator. [0012] EP1201227 discloses a sunscreen formulation comprising an extract of passion flower containing chrysin and/or analogs and Na3H-EDTA as chelator. 55 BRIEF SUMMARY OF THE INVENTION [0013] We have now discovered that the essential characteristics of deteriorated/imperfect skin are frequently the presence of xenobiotics and/or the abnormal accumulation of endogenous substances. In consequence, the use of at 3 EP 1 776 161 B1 least one UGT-inducer could enable a preventive and/or curative effect on deteriorated/imperfect skin to be obtained. [0014] We have also demonstrated the presence of UGT enzymes in the human skin. Stimulation of those cutaneous enzymes has been tested and the topical use of an UGT-inducer to protect the skin and/or enhance its state is proposed. The applicant has discovered that topical application of a UGT-inducer stimulates the expression of those enzymes. 5 [0015] Many compounds have been described as being useful for improving